Tagged with oncology,

USA In 2016, rumours of a weakening FDA followed a disappointing 16 new drugs approved for the full year. However, since the beginning of 2017 the FDA has approved 26 drugs; double the amount of the mid-year average since 2007. “The eight oncology treatments approved by the FDA this year represent…

Colombia Yolanda Alagón, general manager of Janssen Colombia, discusses the company’s footprint in Colombia and Latin America and her strategy for the affiliate moving forward. You have been appointed General Manager three years ago, becoming one of the first women to lead a pharma company in Latin America. You mentioned your…

Colombia Anant Atal, head of Latin America for Cipla, discusses how the establishment of offices in Colombia was facilitated by its longstanding history in the country, the multiple initiatives the company has engaged in with doctors and patients to improve access to treatments in Respiratory, Oncology and HIV, as well as…

Ukraine Vladimir Tkachenko, general manager of AMAXA PHARMA, a UK-headquartered pharmaceutical company focused on life-threatening therapeutic areas such as oncology and neonatology in the CIS countries, provides insights into AMAXA’s market positioning in Ukraine and the region, as well as his strategic priorities to further propel the eye-catching development pace of…

Hong Kong Andy Barnett, general manager (Hong Kong and Macau) for Roche, discusses the highlights of his past two years managing a local affiliate instead of heading a global business line, the key factors behind Roche’s top-5 positioning in the local market, and the huge potential for innovation in aspects like digital…

Colombia Spearheading the Colombian affiliate of the global leader in oncology, Carlos Estrada, General Manager of Roche Colombia shares his insights on the profound transformations of the Colombian healthcare system. He speaks about achieving optimal equilibrium in the system, the exciting pipeline ahead for Roche, as well as their strategies to…

Taiwan James Yang, Director of the Department of Oncology at National Taiwan University Hospital and Director of the Graduate Institute of Oncology at National Taiwan University, discusses the important role of oncology research in developing the Taiwanese pharmaceutical market as well as the new National Taiwanese University Cancer Center (which will…

Taiwan James Chen, founder and Chairman of the board of Vetco, the first Taiwan-based veterinary company to have successfully developed an innovative veterinary oncology product, documents the main specificities of Vetco’s flagship product, Antican®, as well as his strategy to bring this ground-breaking treatment onto the most advanced animal health markets…

Taiwan In an exclusive interview, Amy Huang, general manager of OBI Pharma, shares her plans to bolster the international development of the company and further strengthen its expertise throughout the drug development process. She also elaborates on the key next steps that lie ahead for OBI Pharma’s flagship immuno-oncology therapy, Adagloxad…

Taiwan Founded in 2012, Senhwa Biosciences is mainly engaged in the development and clinical study of small molecule drugs to treat various types of cancer, and its drug development pipelines include CX-5461, a first-in-class drug using G-quadruplex (G4) stabilizer as a mechanism as well as the casein kinase 2 (CK2) inhibitor…

Taiwan Jui-Lin Chen, CEO of MiCareo, provides insights into the development of MiSelect, Micareo’s pioneering platform for the analysis of Circulating Tumor Cells (CTC) and other rare cells, which proudly stands as the best product available to physicians for cancer prognosis as well as the perfect companion diagnostic for drug development…

Taiwan Chen Min-Che, founder and managing director of Asclepiumm, provides insights into the main milestones reached and the new partnership opportunities considered by this exciting biotech company, whose Antibody Switch-on Cytotoxicity (ASC) technology platform could contribute to bringing onto the global market a novel class of “smart cell-penetrating proteins” in multiple…